物质信息
ID:449271
名称和标识
IUPAC标准名
3-(4-amino-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione
别名
RevlimidLenalidomideRevimid
IUPAC传统名
3-(4-amino-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione
数据登录号
CAS号
化合物性质
产品相关信息
应用领域
Used against multiple myeloma and myelodysplastic syndromes
药理学性质
生物活性机理
Interfering with the immune system and angiogenesis
Inhibits the expression of cyclooxygenase-2 (COX-2)
描述信息
暂无数据
点击上传数据
分子图谱
暂无数据
点击上传数据
参考文献
• Bennett et al. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer JAMA 2006;296(21):2558-2560
• Anderson KC. Lenalidomide and thalidomide: mechanisms of action--similarities and differences. Semin Hematol 2005;42(4 Suppl 4):S3-8. PMID 16344099.
• Vellet, S et al Thalidomide and lenalidomide: mechanism-based potential drug combinations Leukemia and Lymphoma 2008;49(7):1238-1245
• List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005;352:549-57. PMID 15703420.
• Weber, DM et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America N Engl Med 2007;357(21):2133-2142
• Chang DH, Liu N, Klimek V, Hassoun H, Mazumder A, Numer SD, Jagannath S, Dhodapkar MV.
• Enhancement of ligand dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 2006;epub ahead of print. PMID 16569772.
• Armoiry, X et al. Lenalidomide in the treatment of multiple myeloma: a review J of Clin Pharmacy & Therapeutics 2008;33:219-226